240 related articles for article (PubMed ID: 24842473)
1. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies.
d'Angelo I; Conte C; La Rotonda MI; Miro A; Quaglia F; Ungaro F
Adv Drug Deliv Rev; 2014 Aug; 75():92-111. PubMed ID: 24842473
[TBL] [Abstract][Full Text] [Related]
2. Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease.
Ibrahim BM; Tsifansky MD; Yang Y; Yeo Y
Expert Opin Drug Deliv; 2011 Apr; 8(4):451-66. PubMed ID: 21375469
[TBL] [Abstract][Full Text] [Related]
3. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
4. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.
Heijerman H; Westerman E; Conway S; Touw D; Döring G;
J Cyst Fibros; 2009 Sep; 8(5):295-315. PubMed ID: 19559658
[TBL] [Abstract][Full Text] [Related]
5. Enhancing adherence to inhaled therapies in cystic fibrosis.
Lomas P
Ther Adv Respir Dis; 2014 Apr; 8(2):39-47. PubMed ID: 24594976
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.
Justo JA; Danziger LH; Gotfried MH
Ther Adv Respir Dis; 2013 Oct; 7(5):272-87. PubMed ID: 23690368
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
8. Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies.
Hurt K; Bilton D
Respiration; 2014; 88(6):441-8. PubMed ID: 25472021
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies in cystic fibrosis.
Anderson P
Ther Adv Respir Dis; 2010 Jun; 4(3):177-85. PubMed ID: 20530065
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for cystic fibrosis.
Amin R; Ratjen F
Expert Opin Emerg Drugs; 2014 Mar; 19(1):143-55. PubMed ID: 24479826
[TBL] [Abstract][Full Text] [Related]
11. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis.
Grasemann H; Kurtz F; Ratjen F
Am J Respir Crit Care Med; 2006 Jul; 174(2):208-12. PubMed ID: 16627863
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
13. New and investigational treatments in cystic fibrosis.
Narasimhan M; Cohen R
Ther Adv Respir Dis; 2011 Aug; 5(4):275-82. PubMed ID: 21372122
[TBL] [Abstract][Full Text] [Related]
14. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients.
Westerman EM; Heijerman HG; Frijlink HW
Expert Opin Drug Deliv; 2007 Mar; 4(2):91-4. PubMed ID: 17335406
[TBL] [Abstract][Full Text] [Related]
15. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
Elborn JS; Henig NR
Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
[TBL] [Abstract][Full Text] [Related]
16. Inhaled aztreonam lysine: an evidence-based review.
Hutchinson D; Barclay M; Prescott WA; Brown J
Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352
[TBL] [Abstract][Full Text] [Related]
17. How can we bring high drug doses to the lung?
Claus S; Weiler C; Schiewe J; Friess W
Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
[TBL] [Abstract][Full Text] [Related]
18. New antimicrobial strategies in cystic fibrosis.
van Westreenen M; Tiddens HA
Paediatr Drugs; 2010 Dec; 12(6):343-52. PubMed ID: 21028914
[TBL] [Abstract][Full Text] [Related]
19. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.
Becker KA; Riethmüller J; Lüth A; Döring G; Kleuser B; Gulbins E
Am J Respir Cell Mol Biol; 2010 Jun; 42(6):716-24. PubMed ID: 19635928
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology approaches for inhalation treatment of fibrosis.
Savla R; Minko T
J Drug Target; 2013 Dec; 21(10):914-25. PubMed ID: 23978292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
